Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates

Group 1 - Ocular Therapeutix reported a quarterly loss of $0.37 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.29, and compared to a loss of $0.24 per share a year ago, indicating an earnings surprise of -27.59% [1] - The company posted revenues of $10.7 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 37.36%, and down from $14.77 million in the same quarter last year [2] - Ocular Therapeutix shares have increased about 3% since the beginning of the year, contrasting with the S&P 500's decline of -3.3% [3] Group 2 - The earnings outlook for Ocular Therapeutix is currently unfavorable, leading to a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] - The current consensus EPS estimate for the upcoming quarter is -$0.29 on revenues of $17.84 million, and for the current fiscal year, it is -$1.19 on revenues of $71.74 million [7] - The Medical - Drugs industry, to which Ocular Therapeutix belongs, is currently in the top 25% of Zacks industries, suggesting a favorable industry outlook [8]